Venaxis, Inc. (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company's test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis. The APPY1 System consists of a small fluorometer (APPYReader Instrument) and consumable test products (APPYReader QC Cassette, APPY1 Controls and APPY1 Test). The APPYReader Instrument measures fluorescence from the APPY1 Test cassette and the APPYReader QC Cassette, the APPYReader QC Cassette enables for functioning of the APPYReader Instrument, and the APPY1 Controls enable functioning of the APPY1 Test components. The APPY1 Test combines the concentrations of over three analytes, such as white blood cell count, C-reactive protein and Venaxis' myeloid-related protein 8/14.